Mabpharm Limited (HKG:2181)
Hong Kong · Delayed Price · Currency is HKD 0.3850
+0.0050 (1.32%)
Jun 12, 2026, 11:11 AM HKT
Mabpharm Market Cap
Mabpharm has a market cap or net worth of 1.59 billion as of June 17, 2026. Its market cap has decreased by -14.44% in one year.
Market Cap
1.59B
Enterprise Value
1.83B
Revenue
718.98M
Ranking
n/a
PE Ratio
34.60
Stock Price
0.39
Market Cap Chart
Since May 31, 2019, Mabpharm's market cap has decreased from 4.99B to 1.59B, a decrease of -68.18%. That is a compound annual growth rate of -14.99%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Jun 16, 2026 | 1.59B | -23.00% |
| Dec 31, 2025 | 2.06B | 78.57% |
| Dec 31, 2024 | 1.15B | -39.13% |
| Dec 29, 2023 | 1.90B | 5.75% |
| Dec 30, 2022 | 1.79B | -56.50% |
| Dec 31, 2021 | 4.12B | -4.76% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro |
| May 31, 2019 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Frontage Holdings | 2.09B |
| HighTide Therapeutics | 1.79B |
| Clover Biopharmaceuticals | 1.71B |
| ImmuneOnco Biopharmaceuticals (Shanghai) | 1.71B |
| SinoMab BioScience | 1.61B |
| Zhaoke Ophthalmology | 1.55B |
| Hangzhou Jiuyuan Genetic Biopharmaceutical | 1.49B |
| Beijing Biostar Pharmaceuticals | 1.16B |